肿瘤药学2016，Vol.6Issue(2)：146-149,4.DOI:10.3969/j.issn.2095-1264.2016.02.12
含脂质体阿霉素方案一线治疗晚期胃癌的疗效和安全性研究
Efficacy and Safety of Liposomal Doxorubicin-based Regimen as First-line Chemotherapy on Advanced Gastric Cancer Patients
马剑 1杨全良 1毕延智 1李小倩 1凌扬1
作者信息
- 1. 苏州大学附属常州肿瘤医院肿瘤内科，江苏 常州，213032
- 折叠
摘要
Abstract
Objective To study on the efficacy and safety of liposomal doxorubicin-based regimen as first-line chemo-therapy on advanced gastric cancer. Methods Twenty-eight patients with advanced gastric cancer but initial treatment were given pegylated liposomal doxorubicin 25 mg·m-2 at d1, oxaliplatin 60 mg·m-2 at d1 and S-1 80 mg·d-1 at d1-14. A circle lasted for 21 days. The response rate and toxicities were evaluated after two cycles. Results Twenty-eight patients were available for evaluation. No case experienced complete remission. There were 15 cases of partial remission, 9 cases of sta-ble disease and 4 cases of progressive disease. The overall response rate was 53.65% (15/28). The median progression-free survival was 8.3 months. Side effects included leucopenia (32.1%), nausea and vomiting (28.6%), thrombocytopenia and so on. Conclusion Pegylated liposomal doxorubicin, oxaliplatin and S-1 as initial treatment had high efficacy and acceptable side effects for advanced gastric cancer patients.关键词
脂质体阿霉素/胃癌/疗效/安全性Key words
Pegylated liposomal doxorubicin/Gastric cancer/Safety/Efficacy分类
医药卫生引用本文复制引用
马剑,杨全良,毕延智,李小倩,凌扬..含脂质体阿霉素方案一线治疗晚期胃癌的疗效和安全性研究[J].肿瘤药学,2016,6(2):146-149,4.
